$MEDXF News
Last published 3y ago
- 3y agoMEDXFMedexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of UnitsGlobeNewswireTORONTO and CHICAGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF), is pleased to announce that it has entered into an agreement
- 3y agoMEDXFMedexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewswireTORONTO and CHICAGO, April 18, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX:MDP, OTCQX:MEDXF) is pleased to announce that company management will be participating in the 2023 Bloom Burton & Co. Healthcare
- 4y agoMEDXFMedexus to Participate in the 34th Annual Roth ConferenceGlobeNewswireTORONTO and CHICAGO, March 09, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) is pleased to announce that it will be participating in the 34th Annual Roth Conference from March 13 to 15, 2022.
- 4y agoMEDXFMedexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021GlobeNewswireAchieved $21.3 million revenue driven by a recovery in IXINITY sales Treosulfan NDA resubmission expected in second calendar quarter 2022 with final FDA decision anticipated 2-6 months after resubmission Available liquidity of $10.1 million at end
- 4y agoMEDXFMedexus to Present at The MicroCap Rodeo's 2nd Annual Winter Wonderland Best Ideas Investor ConferenceGlobeNewswireTORONTO and CHICAGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) is pleased to announce that it will be presenting at The MicroCap Rodeo's 2nd Annual Winter Wonderland Best Ideas
- 4y agoMEDXFMedexus Schedules Third Quarter Fiscal 2022 Conference CallGlobeNewswireTORONTO and CHICAGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, February 10th, 2022, t
- 4y agoACHVCHRAIDAIISDR+436 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022ACCESS NewswireRALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a
- 4y agoMEDXFMedexus to Present at the H.C. Wainwright BioConnect 2022 ConferenceGlobeNewswireTORONTO and CHICAGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that Ken d'Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Offic
- 4y agoMEDXFMedexus to Participate in Two Upcoming Virtual Investor ConferencesGlobeNewswireTORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that Ken d'Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Offic
- 4y agoMEDXFMedexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac's Type A Meeting with FDA on TreosulfanGlobeNewswireNDA resubmission expected in second calendar quarter 2022 (previously anticipated timeline)Final FDA decision expected 2 to 6 months after NDA resubmissionNo additional Phase III study is required TORONTO and CHICAGO, Dec. 02, 2021 (GLOBE NEWSWIR
- 5y agoMEDXFMedexus Pharmaceuticals Reports Financial and Operational Results for the Three- and Six-Month Periods Ending September 30, 2021GlobeNewswireAchieved $17.9 million revenue driven by continued strength of Rupall™ Positioned for revenue growth along with expected recovery of IXINITY® sales Commercially launched Trecondyv® (treosulfan) in Canada Available liquidity of $9.6 million
- 5y agoMEDXFMedexus to Present at the Q4 Investor Summit on November 17thGlobeNewswireTORONTO and CHICAGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being
- 5y agoMEDXFMedexus Pharmaceuticals Announces Appointment of Internal CounselGlobeNewswireTORONTO and CHICAGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) today announced that it has appointed Ian C Wildgoose Brown as the Company's general counsel and corporate secreta
- 5y agoAAZZFABIOACOGFACST+81Investor Summit Group Provides Update on Upcoming Q4 Virtual SummitGlobeNewswireNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4 Virtual Summit on November 16-17. The e
- 5y agoACUALCOALOTAMST+57Sidoti Microcap Virtual ConferenceACCESS NewswireA Conference Open to All Classes of Investors70+ Companies Presenting and Meeting Interested Investors 1x1Wednesday and Thursday, December 8-9, 2021 NEW YORK, NY / ACCESSWIRE / November 5, 2021 / Sidoti & Company, LLC has updated its preliminary list of
- 5y agoMEDXFMedexus Schedules Second Quarter Fiscal 2022 Conference CallGlobeNewswireTORONTO and CHICAGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, November 11, 2021 to
- 5y agoMEDXFMedexus Pharmaceuticals Announces Type A Meeting with FDA Granted for TreosulfanGlobeNewswireTORONTO and CHICAGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) and medac GmbH ("medac") today announced that the U.S. Food and Drug Administration ("FDA") has granted a Type A me
- 5y agoMEDXFMedexus to Present at the Benzinga Global Small Cap Conference on October 28, 2021GlobeNewswireTORONTO and CHICAGO and MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that Ken d'Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Fi
- 5y agoMEDXFMedexus Announces Expanded Availability of Trecondyv® (treosulfan) in CanadaGlobeNewswireTORONTO and CHICAGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) announced today that it has initiated its first commercial shipment of Trecondyv® (treosulfan) in Canada, follow
- 5y agoMEDXFMedexus Holds Annual and Special Meeting of Shareholders and Announces Election of Board of DirectorsGlobeNewswireTORONTO and CHICAGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company") (TSX:MDP) (OTCQX:MEDXF) today held its annual and special meeting of shareholders virtually. At the meeting, all of the nominees listed in the Company'
- 5y agoMEDXFMedexus Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireTORONTO and CHICAGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) today announced that Ken d'Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Offi
- 5y agoMEDXFMedexus Pharmaceuticals Reports Financial and Operational Results for First Quarter Fiscal 2022GlobeNewswireContinued strength in unit demand across key product lines Rupall unit demand growth of 44% for the 12 months ending June 30, 2021 Completion of enrollment for IXINITY® Phase 4 clinical pediatric trials Management to host conference
- 5y agoMEDXFMedexus Completes Enrollment in Phase 4 Clinical Trial of IXINITY® Targeting Label Expansion for Pediatric Hemophilia B PatientsGlobeNewswireTORONTO and CHICAGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that is has completed enrollment in its Phase 4 Clinical Trial of IXINITY®, targeting label expan
- 5y agoMEDXFMedexus Schedules First Quarter Fiscal 2022 Conference CallGlobeNewswireTORONTO and CHICAGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, August 17, 2021 to dis
- 5y agoMEDXFMedexus to Present at Canaccord Genuity's 41st Annual Growth ConferenceGlobeNewswireTORONTO and CHICAGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) announced today that it will be presenting at the Canaccord Genuity 41st Annual Growth Conference being held virtu
- 5y agoMEDXFMedexus Schedules Webinar to Discuss FDA Complete Response Letter for TreosulfanGlobeNewswireTORONTO and CHICAGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) today announced that it has scheduled a webinar on Thursday, August 5, 2021 at 10:00 a.m. Eastern Time to discuss t
- 5y agoMEDXFComplete Response Letter Received from FDA for TreosulfanGlobeNewswireTORONTO and CHICAGO and WEDEL, Germany, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) and medac GmbH ("medac") announced today that medac, Medexus' licensor for treosulfan, has recei
- 5y agoCDNAMEDXFMedexus Appoints New Chief Financial OfficerGlobeNewswireTORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) is pleased to announce the appointment of Marcel Konrad as Chief Financial Officer of the Company, effective immedi
- 5y agoMEDXFMedexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in CanadaGlobeNewswireTORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that it has entered into a licensing agreement, formalizing its relationship wi
- 5y agoMEDXFMedexus Receives Notice of Compliance to Commercialize Treosulfan in CanadaGlobeNewswireTORONTO and CHICAGO, June 28, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that it has received a Notice of Compliance ("NOC") from Health Canada to commercialize treosulfan
- 5y agoMEDXFMedexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021GlobeNewswireTransformative licensing agreement for treosulfan in the U.S. completed February 2, 2021 Cash and cash equivalents of $18.7 million and available liquidity of $24.8 million at March 31, 2021 Management to host conference call at 8:00 AM Eastern Tim
- 5y agoMEDXFMedexus Announces Graduation to the Toronto Stock ExchangeGlobeNewswireTORONTO and CHICAGO and MONTREAL, June 15, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSXV:MDP) (OTCQX:MEDXF) announced today that it has received final approval for listing of the Company's common shares (the "
- 5y agoMEDXFMedexus to Present at Raymond James Human Health Innovation ConferenceGlobeNewswireTORONTO, CHICAGO and MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV:MDP) (OTCQX:MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Raymond James Human Health Innovat
- 5y agoMEDXFMedexus Schedules Fiscal Year 2021 Conference CallGlobeNewswireTORONTO and CHICAGO and MONTREAL, June 11, 2021 (GLOBE NEWSWIRE) -- , June 11, 2021 - Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV:MDP) (OTCQX:MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00
- 5y agoMEDXFMedexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan LaunchGlobeNewswireTORONTO, CHICAGO and MONTREAL, June 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV:MDP) (OTCQX:MEDXF) (Frankfurt: P731) today announced that it has expanded its medical affairs team in preparation for the
- 5y agoMEDXFMedexus Announces Availability of Triamcinolone Hexacetonide in the United StatesGlobeNewswireTORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV:MDP) (OTCQX:MEDXF) (Frankfurt: P731) announced today that it is initiating immediate availability of Triamcinolone Hex
- 5y agoMEDXFMedexus to Present at The LD Micro Virtual Invitational XI on June 8thGlobeNewswireTORONTO and CHICAGO and MONTREAL, June 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV:MDP, OTCQX:MEDXF), today announced that management will present at the LD Micro Invitational XI investor conference taki
- 5y agoMEDXFMedexus Announces Amendments to its Credit AgreementsGlobeNewswireNOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO and CHICAGO and MONTREAL, May 27, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSXV:MDP) (OTCQX:MEDXF)
- 5y agoABMLACUAFIALOT+52Sidoti Microcap Virtual ConferenceACCESS NewswireMay 19 - 20, 2021 Presentation times and weblinks released for over 60 presenting companies NEW YORK, NY / ACCESSWIRE / May 18, 2021 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day spring Microcap Virtual Con
- 5y agoMEDXFMedexus to Present at the Sidoti & Company Virtual Microcap Conference on May 19thGlobeNewswireTORONTO, CHICAGO and MONTREAL, May 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV:MDP) (OTCQX:MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Sidoti & Company Virtual Microcap Co